Physician profile
Brian Bora
NPI 1891892600
$18,302.80
in general payments reported to CMS, 2019-2025
22 companies · $3,901 in 2025
The $3,901 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,572 · 2020: $1,550 · 2021: $1,813 · 2022: $2,789 · 2023: $2,860 · 2024: $3,819 · 2025: $3,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $5.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,573.44 |
| Education | $5.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,303.20 | 2020-2025 | Caplyta |
| Abbvie INC. | $2,265.49 | 2021-2025 | Vraylar |
| Alkermes, INC. | $2,105.86 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $1,930.89 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $1,257.73 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $1,208.44 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $1,033.76 | 2022-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $1,032.72 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $856.70 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $788.39 | 2024-2025 | Cobenfy |
| Corium, LLC | $715.11 | 2022-2024 | Azstarys |
| Allergan, INC. | $634.86 | 2019-2020 | |
| Lundbeck LLC | $539.17 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $465.09 | 2019-2021 | |
| Neos Therapeutics, Lp | $407.36 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $391.03 | 2019-2022 | |
| Adlon Therapeutics L.P. | $166.87 | 2019-2021 | |
| Shire North American Group INC | $109.09 | 2019 | |
| Luye Pharma (USA) Ltd. | $35.84 | 2025 | Erzofri Extended-Release |
| Aytu Biopharma, INC. | $22.07 | 2021 | |
| Bausch Health US, LLC | $19.43 | 2020 | |
| Noven Therapeutics, LLC | $13.70 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.